Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic.
COVID-19
Covid-19
SARS-CoV-2
antidiabetic medications
diabetes mellitus
hydroxychloroquine
严重急性呼吸综合征冠状病毒2
糖尿病
羟基氯喹
降糖药物
Journal
Journal of diabetes
ISSN: 1753-0407
Titre abrégé: J Diabetes
Pays: Australia
ID NLM: 101504326
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
24
04
2020
revised:
10
05
2020
accepted:
12
05
2020
pubmed:
14
5
2020
medline:
14
8
2020
entrez:
14
5
2020
Statut:
ppublish
Résumé
The antimalarial drug hydroxychloroquine (HCQ) has long been used as a disease-modifying antirheumatic drug for the treatment of several inflammatory rheumatic diseases. Over the last three decades, various studies have shown that HCQ also plays a role in the regulation of glucose homeostasis. Although the mechanisms of action underlying the glucose-lowering properties of HCQ are still not entirely clear, evidence suggests that this drug may exert multifaceted effects on glucose regulation, including improvement of insulin sensitivity, increase of insulin secretion, reduction of hepatic insulin clearance, and reduction of systemic inflammation. Preliminary studies have shown the safety and efficacy of HCQ (at a dose ranging from 400 to 600 mg/day) in patients with type 2 diabetes over a short-term period. In 2014, HCQ has been approved in India as an add-on hypoglycemic agent for patients with uncontrolled type 2 diabetes. However, large randomized controlled trials are needed to establish the safety and efficacy profile of HCQ in patients with type 2 diabetes over a long-term period. With regard to the COVID-19 pandemic, several medications (including HCQ) have been used as off-label drugs because of the lack of proven effective therapies. However, emerging evidence shows limited benefit from HCQ use in COVID-19 in general. The aim of this manuscript is to comprehensively summarize the current knowledge on the antihyperglycemic properties of HCQ and to critically evaluate the potential risks and benefits related to HCQ use in patients with diabetes, even in light of the current pandemic scenario. 抗疟药羟基氯喹(HCQ)长期以来一直作为一种缓解症状的药物, 用于多种炎症性风湿病的治疗。在过去的三十年里, 各种研究表明HCQ在调节葡萄糖稳态方面也起着作用。虽然HCQ的降糖作用机制尚不完全清楚, 但有证据表明该药可能具有多方面的血糖调节作用, 包括改善胰岛素敏感性, 增加胰岛素分泌, 降低肝脏胰岛素清除率和减轻全身炎症。初步研究表明, HCQ(每天剂量从400 - 600毫克)对2型糖尿病患者短期内是安全和有效的。2014年, HCQ在印度被批准作为未受控制的2型糖尿病患者的附加降糖药。然而, 仍然需要大型随机对照试验来确定HCQ在2型糖尿病患者中的长期安全性和有效性。在新冠肺炎大流行期间, 由于缺乏被证明有效的治疗方法, 几种药物(包括HCQ)已在超适应症应用。可是, 新出现的证据显示, 总的来说新冠肺炎使用HCQ的益处是有限的。本文献旨在当前新冠大流行情况下, 全面总结目前关于HCQ降血糖特性的知识, 并严格评估与HCQ在糖尿病患者中使用相关的潜在风险和好处。.
Autres résumés
Type: Publisher
(chi)
抗疟药羟基氯喹(HCQ)长期以来一直作为一种缓解症状的药物, 用于多种炎症性风湿病的治疗。在过去的三十年里, 各种研究表明HCQ在调节葡萄糖稳态方面也起着作用。虽然HCQ的降糖作用机制尚不完全清楚, 但有证据表明该药可能具有多方面的血糖调节作用, 包括改善胰岛素敏感性, 增加胰岛素分泌, 降低肝脏胰岛素清除率和减轻全身炎症。初步研究表明, HCQ(每天剂量从400 - 600毫克)对2型糖尿病患者短期内是安全和有效的。2014年, HCQ在印度被批准作为未受控制的2型糖尿病患者的附加降糖药。然而, 仍然需要大型随机对照试验来确定HCQ在2型糖尿病患者中的长期安全性和有效性。在新冠肺炎大流行期间, 由于缺乏被证明有效的治疗方法, 几种药物(包括HCQ)已在超适应症应用。可是, 新出现的证据显示, 总的来说新冠肺炎使用HCQ的益处是有限的。本文献旨在当前新冠大流行情况下, 全面总结目前关于HCQ降血糖特性的知识, 并严格评估与HCQ在糖尿病患者中使用相关的潜在风险和好处。.
Identifiants
pubmed: 32401405
doi: 10.1111/1753-0407.13053
pmc: PMC7272905
doi:
Substances chimiques
Antiviral Agents
0
Hypoglycemic Agents
0
Hydroxychloroquine
4QWG6N8QKH
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
659-667Informations de copyright
© 2020 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.
Références
PLoS One. 2018 Dec 6;13(12):e0208321
pubmed: 30521586
J Diabetes Res. 2020 Feb 27;2020:5214751
pubmed: 32190699
J Clin Rheumatol. 2013 Aug;19(5):286-8
pubmed: 23872551
Ophthalmology. 2016 Jun;123(6):1386-94
pubmed: 26992838
Arthritis Care Res (Hoboken). 2018 Mar;70(3):481-485
pubmed: 28556555
J Diabetes. 2020 Jul;12(7):486-487
pubmed: 32353193
Sci Rep. 2017 Jul 26;7(1):6619
pubmed: 28747790
Infez Med. 2020 Ahead of print Jun 1;28(2):143-152
pubmed: 32275256
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Biochem Biophys Res Commun. 2013 Jun 14;435(4):708-13
pubmed: 23702482
Ann Intern Med. 1990 May 1;112(9):678-81
pubmed: 2110430
Lancet Diabetes Endocrinol. 2016 Jan;4(1):20-1
pubmed: 26724596
J Clin Invest. 2017 Jan 3;127(1):14-23
pubmed: 28045399
Circulation. 2020 Jun 16;141(24):e906-e907
pubmed: 32267732
J Endocrinol Invest. 2020 Jun;43(6):867-869
pubmed: 32222956
Diabetes Res Clin Pract. 2002 Mar;55(3):209-19
pubmed: 11850097
J Rheumatol. 2000 Dec;27(12):2927-31
pubmed: 11128688
Lancet Diabetes Endocrinol. 2015 Oct;3(10):758-60
pubmed: 26386988
Clin Toxicol (Phila). 2006;44(2):173-5
pubmed: 16615675
JAMA Cardiol. 2020 Sep 01;5(9):1036-1041
pubmed: 32936252
Diabetes Metab Res Rev. 2020 Mar 31;:e3319
pubmed: 32233013
Case Rep Cardiol. 2016;2016:4626279
pubmed: 27478650
Arthritis Res Ther. 2012 Jun 07;14(3):R135
pubmed: 22676348
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Curr Med Res Opin. 2014 Jul;30(7):1257-66
pubmed: 24669876
Diabetes Metab. 2012 Jun;38(3):183-91
pubmed: 22252015
J Clin Rheumatol. 2011 Apr;17(3):115-20
pubmed: 21441823
J Clin Rheumatol. 2010 Jan;16(1):28-31
pubmed: 20051753
Diabet Med. 2013 Jul;30(7):803-17
pubmed: 23413806
J Diabetes. 2020 Jan;12(1):91-94
pubmed: 31574564
Arthritis Care Res (Hoboken). 2014 Aug;66(8):1246-51
pubmed: 24470436
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
Nat Rev Rheumatol. 2020 Mar;16(3):155-166
pubmed: 32034323
Diabetes. 2017 Jun;66(6):1432-1442
pubmed: 28533294
Eur J Haematol. 2020 Sep;105(3):357-359
pubmed: 32324284
Am J Hematol. 2005 Apr;78(4):306-9
pubmed: 15795921
J Clin Invest. 2006 Jul;116(7):1784-92
pubmed: 16823476
JAMA Cardiol. 2020 Sep 1;5(9):1067-1069
pubmed: 32936266
JAMA. 2007 Jul 11;298(2):187-93
pubmed: 17622600
Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E736-E741
pubmed: 32228322
Can J Physiol Pharmacol. 1999 Feb;77(2):118-23
pubmed: 10535702
Int J Diabetes Dev Ctries. 2018 Mar;38(Suppl 1):1-115
pubmed: 29527102
Semin Immunopathol. 2019 Jul;41(4):501-513
pubmed: 30989320
Rheumatology (Oxford). 2008 Mar;47(3):378-9
pubmed: 18222983
Mil Med Res. 2020 May 5;7(1):22
pubmed: 32370766
Diabetes Care. 2012 Aug;35(8):e58
pubmed: 22826451
N Engl J Med. 2020 Mar 26;382(13):1268-1269
pubmed: 32109011
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):395-403
pubmed: 32334395
Rheumatology (Oxford). 2015 Jul;54(7):1244-9
pubmed: 25587177
Clin Ther. 2020 May;42(5):940-945
pubmed: 32336573
Indian Pacing Electrophysiol J. 2020 May - Jun;20(3):117-120
pubmed: 32278018
Can J Cardiol. 2020 Jun;36(6):948-951
pubmed: 32299753
BMJ Case Rep. 2018 Apr 18;2018:
pubmed: 29669768
Am J Physiol. 1991 Jun;260(6 Pt 1):E897-904
pubmed: 2058666
Life Sci. 1999;64(5):325-35
pubmed: 10072192
N Engl J Med. 2020 Jun 18;382(25):2461-2462
pubmed: 32379956
JAMA Cardiol. 2020 Sep 1;5(9):986-987
pubmed: 32936259
Diabetologia. 2015 Oct;58(10):2336-43
pubmed: 26197707
J Assoc Physicians India. 2019 Dec;67(12):65-74
pubmed: 31801334
Ann Rheum Dis. 2006 Mar;65(3):385-90
pubmed: 16096334
Nat Rev Cardiol. 2017 Sep;14(9):521-535
pubmed: 28470179
Arthritis Rheum. 2010 Dec;62(12):3569-73
pubmed: 20722019
Diabetes Ther. 2017 Jun;8(3):475-487
pubmed: 28484968
Arthritis Rheum. 1987 Feb;30(2):221-4
pubmed: 3030337
Nat Rev Immunol. 2011 Feb;11(2):98-107
pubmed: 21233852
N Engl J Med. 2020 Jun 18;382(25):2411-2418
pubmed: 32379955
Curr Diabetes Rev. 2019;15(6):510-519
pubmed: 31713476
Genet Med. 2006 Mar;8(3):143-55
pubmed: 16540748
QJM. 2019 Oct 1;112(10):757-762
pubmed: 31218368
J Clin Rheumatol. 2011 Jan;17(1):46-7
pubmed: 21169846
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
J Rheumatol. 1999 Jan;26(1):195-6
pubmed: 9918262
Lancet Diabetes Endocrinol. 2016 Jan;4(1):19-20
pubmed: 26724595
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
Diabet Med. 2020 Aug;37(8):1404-1405
pubmed: 31557353
Nat Rev Endocrinol. 2020 Jun;16(6):297-298
pubmed: 32242089
Endocr Rev. 2020 Jun 1;41(3):
pubmed: 32294179
J Diabetes. 2020 Sep;12(9):659-667
pubmed: 32401405
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Lancet Infect Dis. 2003 Nov;3(11):722-7
pubmed: 14592603
Eye (Lond). 2017 Jun;31(6):828-845
pubmed: 28282061
JAMA. 2011 Jun 22;305(24):2525-31
pubmed: 21693740
Drugs. 2019 Jan;79(1):43-61
pubmed: 30612319
Neurology. 2019 Feb 12;92(7):e742-e745
pubmed: 30745451